Amiodarone Black Box Warnings
Amiodarone carries FDA black box warnings for pulmonary toxicity (potentially fatal), hepatotoxicity, and proarrhythmic effects—these life-threatening risks mandate that the drug be reserved only for patients with life-threatening recurrent ventricular arrhythmias who have failed other therapies. 1
Critical Black Box Warning Categories
1. Pulmonary Toxicity (Most Serious)
- Fatal pulmonary toxicity can occur including pneumonitis and pulmonary fibrosis 2
- Occurs at a rate of 1% annually with modern dosing (≤300 mg/day), but historically ranged 2-17% 2
- Can develop rapidly without antecedent abnormalities on chest X-ray or pulmonary function tests 2
- Presents as subacute cough and progressive dyspnea with patchy interstitial infiltrates 2
- Must rule out congestive heart failure as it mimics amiodarone pneumonitis 2
- Treatment requires immediate amiodarone withdrawal, supportive care, and often corticosteroids 2
2. Hepatotoxicity
- Acute centrolobular confluent hepatocellular necrosis can lead to hepatic coma, acute renal failure, and death 1
- Particularly associated with excessive loading dose concentrations and rapid infusion rates 1
- Chronic liver toxicity with transaminase elevation occurs at 0.6% annually 2
- Discontinue if liver enzymes exceed 3× normal unless patient is at high risk for life-threatening arrhythmia recurrence 2
3. Proarrhythmic Effects
- Can cause life-threatening arrhythmias including torsades de pointes, though rare despite universal QT prolongation 2
- Annual proarrhythmia rate <1% 2
- Contraindicated in second- or third-degree heart block without pacemaker 2
4. Thyroid Dysfunction
- Both hypothyroidism (2-10% of patients) and hyperthyroidism (2% of patients) can occur 1
- Amiodarone-induced thyrotoxicosis can be fatal and may cause arrhythmia breakthrough 1
- Hyperthyroidism poses greater hazard than hypothyroidism due to potential for thyrotoxicosis and death 1
- Any new arrhythmia signs should prompt evaluation for hyperthyroidism 1
- Thyroid storm can occur with surgical thyroidectomy for amiodarone-induced thyrotoxicosis 1
- Postmarketing reports of thyroid nodules/thyroid cancer 1
5. Cardiovascular Effects (IV Formulation)
- Hypotension is most common adverse effect (16% of patients) with IV amiodarone 1
- Drug-related bradycardia occurs in 4.9% of IV patients 1
- Hypotension is rate-related, not dose-related; treat by slowing infusion 1
- Can be refractory and fatal 1
Mandatory Restriction
Amiodarone is indicated ONLY for treatment of life-threatening recurrent ventricular arrhythmias (ventricular fibrillation or hemodynamically unstable ventricular tachycardia) in patients refractory to other therapy or when alternative agents cannot be tolerated. The substantial toxicity risk requires that physicians use the lowest effective dose and discontinue if possible 2.
Critical Drug Interactions Requiring Monitoring
- Warfarin: Sudden pronounced INR increases; monitor INR at least weekly for first 6 weeks 2
- Digoxin: Levels predictably double; reduce digoxin dose by 50% when starting amiodarone 2
- Grapefruit juice: Increases amiodarone levels by 50-84%; must be avoided 1
- Multiple CYP450 interactions (CYP3A4, CYP2D6, CYP2C9) 1
Perioperative Warning
Patients are more sensitive to myocardial depressant and conduction effects of halogenated inhalational anesthetics; close perioperative monitoring mandatory 1. Most corneal refractive laser surgery manufacturers contraindicate the procedure in amiodarone patients 1.
Pediatric Black Box Consideration
Contains benzyl alcohol preservative which has caused fatal "gasping syndrome" in neonates; safety and efficacy not established in pediatric patients 1.